Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.31 |
| ▸ | GPR3 | P46089 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17742402 | 0.87 | PTGIR (0.44) | PTGIRMAPTDHODHPARP14GPR3 | |
| SCHEMBL25124742 | 0.84 | PDK2 (0.37) | MAPTHPGDSMN1; SMN2PDK2 | |
| SCHEMBL25125149 | 0.84 | ALOX5 (0.36) | PTGIRMAPTALOX5PARP14GPR3 | |
| SCHEMBL21446453 | 0.83 | PARP14 (0.49) | PTGIRMAPTALOX5PARP14PDK2 | |
| SCHEMBL22136344 | 0.83 | PTGIR (0.34) | PTGIRMAPTDHODHPDK2 | |
| SCHEMBL22679979 | 0.83 | RIPK2 (0.37) | PTGIRMAPTPDK2 | |
| SCHEMBL19147810 | 0.82 | RIPK2 (0.35) | PTGIRMAPTALDH1A1HPGDRAB9A | |
| SCHEMBL23371584 | 0.82 | MAPT (0.42) | PTGIRMAPTDHODHGPR3ALDH1A1 | |
| SCHEMBL15714096 | 0.82 | PDK2 (0.38) | PTGIRMAPTALOX5DHODHGPR3 | |
| SCHEMBL21446457 | 0.81 | MAPT (0.35) | PTGIRMAPTALOX5DHODHPARP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11711973-B2 | Organic electronic device | DUK SAN NEOLUX CO., LTD. (KR) | 2023-07-25 | — | — | US | disclosed |
| US-11711973-B2 | Organic electronic device | DUK SAN NEOLUX CO., LTD. (KR) | 2023-07-25 | — | — | US | disclosed |
| US-20210147375-A1 | MATERIALS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2021-05-20 | — | — | US | disclosed |
| WO-2019192954-A1 | MATERIALS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2019-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147375-A1 | MATERIALS FOR ELECTRONIC DEVICES | PNMT, EFNA1, TES | PTGIR 2841/4885MAPT 2579/4885ALOX5 2210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.